PlumX Metrics
Embed PlumX Metrics

Evidence of neurodegeneration in autism spectrum disorder

Translational Neurodegeneration, ISSN: 2047-9158, Vol: 2, Issue: 1, Page: 17
2013
  • 63
    Citations
  • 0
    Usage
  • 122
    Captures
  • 1
    Mentions
  • 128
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    63
  • Captures
    122
  • Mentions
    1
    • News Mentions
      1
      • 1
  • Social Media
    128
    • Shares, Likes & Comments
      128
      • Facebook
        128

Most Recent News

Entia Biosciences and BioCheck to Develop Companion Diagnostics

Entia Biosciences (Entia; OTCQB: ERGO), a food science biotechnology company and emerging leader in the field of Nutrigenomics, has engaged BioCheck Inc., of Foster City,

Review Description

Autism spectrum disorder (ASD) is a neurological disorder in which a significant number of children experience a developmental regression characterized by a loss of previously-acquired skills and abilities. Loss of neurological function in ASD, as observed in affected children who have regressed, can be explained as neurodegeneration. Although there is research evidence of neurodegeneration or progressive encephalopathy in ASD, the issue of neurodegeneration in ASD is still under debate. Evidence of neurodegeneration in the brain in ASD includes: (1) neuronal cell loss, (2) activated microglia and astrocytes, (3) proinflammatory cytokines, (4) oxidative stress, and (5) elevated 8-oxo-guanosine levels. The evidence from this review suggests that neurodegeneration underlies the loss of neurological function in children with ASD who have experienced regression and loss of previously acquired skills and abilities, and that research into treatments to address the issue of neurodegeneration in ASD are warranted. © 2013 Kern et al.; licensee BioMed Central Ltd.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know